Human CXCL7/NAP-2 Antibody

Name: Human CXCL7/NAP-2 Antibody
Brand: R&D Systems
SKU: MAB393
Rating: 5 (1 reviews)

Catalog #: MAB393
6 Citations 1 Review Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB393
MAB393-SP

Myeloperoxidase Release Induced by CXCL7/NAP‑2 and Neutralization by Human CXCL7/NAP‑2 Antibody.

2 Images

All CXCL7/NAP-2 Antibodies

Product Details

Citations (6)

FAQs

Supplemental Products

Reviews (1)

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human CXCL7/NAP-2 Antibody Summary

Species Reactivity

Human

Specificity

Detects human CXCL7/NAP‑2 in ELISAs and Western blots. In sandwich ELISAs, less than 0.05% cross-reactivity with recombinant human (rh) CXCL1, 2, 3, 5, 6, 8, 9, 10, or 12 is observed. In Western blots, no cross-reactivity with rhCXCL1, 2, 3, 5, 6, 8, 9, 10, 12, 13, recombinant mouse CXCL1, 2, 6, 9, 10, 12 or recombinant rat CXCL1, 2 or 3 is observed.

Source

Monoclonal Mouse IgG₁ Clone # 59418

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

E. coli-derived recombinant human CXCL7/NAP-2
Ala59-Asp128
Accession # P02775

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Western Blot

1 µg/mL

Recombinant Human CXCL7/NAP‑2 (Catalog # 393-NP)

Simple Western

10 µg/mL

See below

Human CXCL7/NAP-2 Sandwich Immunoassay

Recommended Concentration

Reagent

ELISA Capture (Matched Antibody Pair)

2-8 µg/mL

Use in combination with:

Detection Reagent: Human CXCL7/NAP‑2 Biotinylated Antibody (Catalog # BAF393)

Standard: Recombinant Human CXCL7/NAP-2 Protein (Catalog # 393-NP)

Neutralization

Measured by its ability to neutralize CXCL7/NAP‑2-induced myeloperoxidase release in cytochalasin‑B treated human neutrophils. Schröder, J. M. et al. (1987) J. Immunol. 139:3474. The Neutralization Dose (ND₅₀) is typically 15-20 µg/mL in the presence of 1 µg/mL Recombinant Human CXCL7/NAP‑2 and cytochalasin‑B.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

Myeloperoxidase Release Induced by CXCL7/NAP‑2 and Neutralization by Human CXCL7/NAP‑2 Antibody. Recombinant Human CXCL7/NAP-2 (Catalog # 393-NP) induces myeloperox-idase release in the cytochalasin-B treated human neutrophils in a dose-dependent manner (orange line). Myeloperoxidase Release elicited by Recombinant Human CXCL7/NAP-2 (1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CXCL7/ NAP-2 Monoclonal Antibody (Catalog # MAB393). The ND₅₀ is typically 15-20 µg/mL in the presence of cytochalasin-B.

Simple Western

View Larger

Detection of Human CXCL7/NAP‑2 by Simple Western^TM. Simple Western lane view shows lysates of human platelets, loaded at 0.2 mg/mL. A specific band was detected for CXCL7/NAP‑2 at approximately 10 kDa (as indicated) using 10 µg/mL of Mouse Anti-Human CXCL7/NAP‑2 Monoclonal Antibody (Catalog # MAB393). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CXCL7/NAP-2

CXCL7, also known as NAP-2, is a 11 kDa angiogenic alpha -chemokine that is produced by the proteolytic cleavage of the inactive 13 kDa platelet basic protein (PBP). PBP, CXCL7, and C-terminally truncated forms of CXCL7 are secreted by monocytes and platelets. Active CXCL7 binds CXCR2 and induces the chemoattration of monocytes, neutrophils, and endothelial progenitor cells. It also inhibits megakaryocytopoiesis in the bone marrow. Within the region included in this immunogen, human CXCL7 shares 52% aa sequence identity with mouse and rat CXCL7.

Entrez Gene IDs

5473 (Human)

Alternate Names

Beta-TG; connective tissue-activating peptide III; CTAP III; CTAP3CTAP-III; CTAPIII; CXC chemokine ligand 7; C-X-C motif chemokine 7; CXCL7; CXCL7b-TG1; LA-PF4; LDGFTC1; Leukocyte-derived growth factor; low-affinity platelet factor IV; Macrophage-derived growth factor; MDGFTC2; NAP2; NAP-2; NAP-2-L1; neutrophil-activating peptide 2; neutrophil-activating peptide-2; PBPTHBGB; platelet basic protein; PPBP; pro-platelet basic protein (chemokine (C-X-C motif) ligand 7); SCAR10; SCYB7beta-thromboglobulin; small inducible cytokine B7; small inducible cytokine subfamily B, member 7; Small-inducible cytokine B7; TGB; TGB1B-TG1; THBGB1; thrombocidin 1; thrombocidin 2; thromboglobulin, beta-1

Product Datasheets

Product Datasheet

COA

SDS

Related Research Areas

Citations for Human CXCL7/NAP-2 Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

6 Citations: Showing 1 - 6
Filter your results:

Filter by:

Effect of platelet-derived ?-thromboglobulins on coagulation
Authors: K Egan, JP van Geffen, H Ma, B Kevane, A Lennon, S Allen, E Neary, M Parsons, P Maguire, K Wynne, R O' Kennedy, JW Heemskerk, FN Áinle
Thromb. Res., 2017-03-30;154(0):7-15.
Species: Human
Sample Types: Plasma
Applications: Functional Assay
Development of a Glycosaminoglycan Derived, Selectin Targeting Anti-Adhesive Coating to Treat Endothelial Cell Dysfunction
Authors: JR Wodicka, AM Chambers, GS Sangha, CJ Goergen, A Panitch
Pharmaceuticals (Basel), 2017-03-29;10(2):.
Species: Human
Sample Types: Platelet Rich Plasma (PRP)
Applications: ELISA Development (Capture)
Up-regulation of platelet activation in hemophilia A.
Authors: van Bladel ER, Roest M
Haematologica, 2011-03-21;0(0):.
Species: Human
Sample Types: Plasma
Applications: ELISA Development
High platelet reactivity is associated with myocardial infarction in premenopausal women: a population-based case-control study.
Authors: Snoep JD, Roest M, Barendrecht AD
J. Thromb. Haemost., 2010-01-30;8(5):906-13.
Species: Human
Sample Types: Plasma
Applications: ELISA Development
Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation.
Authors: Smith C, Damas JK, Otterdal K, ÃƒËœIe E, Sandberg WJ, Yndestad A, Waehre T, Scholz H, Endresen K, Olofsson PS, Halvorsen B, Gullestad L, Froland SS, Hansson GK, Aukrust P
J. Am. Coll. Cardiol., 2006-09-27;48(8):1591-9.
Species: Human
Sample Types: Whole Cells
Applications: Neutralization
Identifying platelet-derived factors as amplifiers of B. burgdorferi-induced cytokine production
Authors: Mariska Kerstholt, Freek R van de Schoor, Marije Oosting, Simone J C F M Moorlag, Yang Li, Martin Jaeger et al.
Clinical and Experimental Immunology